Mathiasen Victor Dahl, Oversoe Stine Karlsen, Ott Peter, Jensen-Fangel Søren, Leth Steffen
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Transplant Proc. 2020 Nov;52(9):2703-2706. doi: 10.1016/j.transproceed.2020.09.007. Epub 2020 Sep 17.
The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an enormous impact on the world. Owing to limited data available, it remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease. We describe a moderate course of coronavirus disease 2019 (COVID-19) in a patient who underwent a liver transplant 2 years earlier because of Budd-Chiari syndrome. The patient presented with malaise, headache, dry cough, and fever for 4 days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection. Oxygen therapy was given for a single night, and the patient gradually recovered with supportive care only. With this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with higher mortality.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的全球大流行对世界产生了巨大影响。由于可用数据有限,目前尚不清楚肝移植受者在多大程度上应被视为患重症疾病的高风险人群。我们描述了一名因布加综合征在两年前接受肝移植的患者,其2019冠状病毒病(COVID-19)病程较为温和。该患者出现不适、头痛、干咳和发热4天。在整个感染过程中持续使用他克莫司和霉酚酸酯进行免疫抑制治疗。仅吸氧一晚,患者仅通过支持治疗逐渐康复。通过本病例报告,我们证明肝移植和免疫抑制不一定与重症COVID-19相关,并强调迫切需要更多关于此事的信息。停用免疫抑制治疗可能与更高的死亡率相关。